A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition

BACKGROUND: Malignant Mesothelioma (MM) is a highly aggressive tumor with poor prognosis. Multimodal treatments and novel molecular targeted therapies against MM are in high demand in order treat this disease effectively. We have developed a humanized monoclonal antibody YS110 against CD26 expressed...

詳細記述

保存先:
書誌詳細
出版年:Cancer Cell Int
主要な著者: Hayashi, Mutsumi, Madokoro, Hiroko, Yamada, Koji, Nishida, Hiroko, Morimoto, Chikao, Sakamoto, Michiie, Yamada, Taketo
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2016
主題:
Primary Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4851800/
https://ncbi.nlm.nih.gov/pubmed/27134571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-016-0310-9
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料